5FONTANA P, DUPONT A, GANDRILLE S, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects [ J ]. Circulation,2003, 108(8):989 -995. 被引量：1
6MEHTA SR, YUSUF S, PETERS RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study[J]. Lancet, 2000, 358(9281):527 -533. 被引量：1
7YUSUF S, ZHAO F, MEHTA SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-elevation[ J ]. N Engl J Med , 2001, 345 (7) :494 -502 被引量：1
8NGUYEN TA, DIODATI JG, PHARAND C. Resistance to clopidogrel : a review of the evidence[ J]. J Am Coll Cardiol, 2005, 45(8) :1157 -1164. 被引量：1
9VON BECKERATH N, VON BECKERATH O, KOCH W, et al. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose [ J ]. Blood Coagul Fibrinolysis, 2005, 16 ( 3 ) : 199 - 204. 被引量：1
10ANGIOLILLO DJ, FERNANDEZ-ORTIZ A, BERNARDO E, et al. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease[J]. Thromb Res, 2005, 116(6) :491 -497. 被引量：1
4Kushner FG,Hand M, Smith SJ,et al. 2009 focused up dates:ACC/AHA guidelines for the management of pa tients with ST elevation myocardial infarction (updatin the 2004 guideline and 2007 focused update) and ACC/ AHA/SCAI guidelines on percutaneous coronary inter vention (updating the 2005 guideline and 2007 focused up date) a report of the American College of Cardiolog3 Foundation/American Heart Association Task Force or Practice Guidelines[J]. J Am Coll Cardiol, 54 (23) : 2205 2241. 被引量：1
5Angiolillo DJ,F'ernandez-Ortiz A, Bernardo E, et al. Vari- ability in individual responsiveness to elopidogrel - Clinical implications, management, and future perspectives [J]. J Am Coll Cardiol,2007,49(14) :1505 1516. 被引量：1
6Miao J, Liu R, Li Z. Cytochrome P 450 polymorphisms and response to clopidogrel[J]. N Engl J Med, 2009,360 (21) : 2250-2251. 被引量：1
7Harmsze AM, van Werkum JW, Ten Berg JM, et al. CYP2C19 ± 2 and CYP2C9 ± 3 alleles are associated with stent thrombosis: a case-control study[J]. Eur Heart J, 2010,31 (24) : 3046-3053. 被引量：1
8Malek LA, Kisiel B, Spiewak M, et al. Coexisting poly morphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel[J]. Cite J,2008,72(7) : 1165-1169. 被引量：1
9Trenk D, Hochholzer W,Fromm MF,et al. Cytochrome P450 2C19 681G~>A polymorphism and high on-clopidogrel plate- let reactivity associated with adverse 1 year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents[J]. J Am Coil Cardiol, 2008,51 (20) : 1925 1934. 被引量：1
10H ulot JS,Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19 ± 2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis [J]. J Am CoU Cardiol, 2010,56(2) : 134-143. 被引量：1
